MedTrace Logo

ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery

NCT01046942 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2013-09-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether adding clopidogrel to aspirin after coronary bypass operation (CABG) improves graft patency, in patients that have preoperatively increased platelet activity(hypercoagulable) and therefore greater risk of graft occlusion( thrombosis).

Conditions

  • Graft Patency
  • Coronary Artery Bypass Grafting Surgery
  • Hypercoagulability
  • Thrombosis

Interventions

DRUG

Clopidogrel+acetylsalicylic acid

loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery

DRUG

acetylsalicylic acid

aspirin 75 mg daily, started 6-24 hours after surgery

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Sulman Rafiq, MD · Dept. of Cardiothoracic Surgery, Rigshospitalet, Copenhagen University Hospital

  • Daniel Steinbrüchel, Professor · Dept. of Cardiothoracic Surgery, Rigshospitalet, Copenhagen University Hospital

  • Pär Johansson, cons. MD,MPA · Blood Bank, Rigshospitalet, Copenhagen University Hospital

  • Klaus Kofoed, cons.MD · Dep. of Cardiology, Rigshospitalet,Copenhagen University Hospital

  • Mette Zacho, MD · Dept. of Radiology, Rigshospitalet, Copenhagen University Hospital

  • Trine Stissing, MD · Blood Bank, Rigshospitalet, Copenhagen University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2014-05-31
Completion
2014-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01046942 on ClinicalTrials.gov